Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02298985
Other study ID # VLJB-14
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 2015
Est. completion date May 2017

Study information

Verified date January 2019
Source Beersheva Mental Health Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Schizophrenia is still remained one of the disabling disorders despite progress in treatment of mental disturbances. Ten to thirty percents of patients have a little or no benefit from treatment with all kinds of antipsychotics using adequate dosages and duration. Treatment of these patients has remained a persistent public health problem since medication-resistant patients are often highly symptomatic. Curcumin is one of the main curcuminoids isolated from this perennial herb. It possesses a variety of pharmacological activities, including anti-inflammatory, antiproliferative, antioxidant, and neuroprotective effects and crosses the blood-brain barrier. The purpose of our suggested study is to examine the efficacy of curcumin as add-on the conventional antipsychotic psychopharmacotherapy in chronic schizophrenia patients.


Description:

Study Design This is a 24-week, randomized, double-blind, placebo-controlled investigation of 40 chronic schizophrenia patients.

Participants Forty patients will be drawn from the patient population of Be'er Sheva Mental Health Center. Recruitment period will last over 2 years.

Patients will be required to have a primary diagnosis of chronic schizophrenia as defined in DSM-IV with predominantly persistent negative signs.

The study will commence only after approval by the local Institutional Ethics Review Board ("Helsinki Committee"). Only willing subjects and able to provide written informed consent, after receiving a comprehensive explanation of the study procedures, will be included in the study. Confidentially will be ensured by means of a number coding system, and all completed research forms will be stored in secure areas.

Procedure Patients will continue receiving their regular antipsychotic medication. The dose will be kept constant for at least 3 months prior to entry and throughout the study period. Curcumin is provided as Curcumin Forte ® (Solgar Israel SupHerb). Circumin capsules are supplied as an 1000 mg soft gelatin capsule for three daily oral administration with meals. At entry patients will receive curcuma capsules (3000 mg/day, three capsules) or placebo in identical capsules in a randomized, double blind mode for 24 weeks: 20 patients will receive curcumin, and 20 patients - placebo.

Participants will be assessed at baseline and after 4, 8, 12, 16 and 24 weeks of treatment. In a case of treatment discontinuation for 24-week of the trial, patients will be followed until end of study period.

Outcome variables will be evaluated by scoring the severity of symptoms (positive, negative, and etc.), and side effects. In addition, liver function tests and a blood cell count will be monitored at baseline and during the study.

For analyzing the results, within-subject pre- and post-treatment responses would be subject to statistical procedures to evaluate whether curcumin can ameliorate the persistent negative symptoms in schizophrenia.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date May 2017
Est. primary completion date January 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Age 18-60 years, male or female

- DSM-IV criteria for schizophrenia.

- Ability and willingness to sign informed consent for participation in the study

- SANS (Scale of Negative Symptoms of Schizophrenia ) > 30 points

- Fixed antipsychotic dosages at least 3 months

- Steady mental state of patients at least 3 months

Exclusion Criteria:

- Current substance use disorder except nicotine dependence

- Regular use of NSAID (non-steroidal anti-inflammatory drugs)

- Cancer history

- Untreated or severe hypertension

- Poorly controlled diabetes mellitus Type I or Type II

- Chronic liver & gallbladder diseases

- Recent GERD (Gastroesophageal Reflux Disorder)

- Neurological disorders: epilepsy, stroke

- Hamilton Depression Scale Hamilton Depression Rating Scale (HAM-D-17 item) > 24 points

- Patients with a known hypersensitivity to curcumin

- Pregnant women or a woman who intends to become pregnant

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Curcumin
3 g/day (3 capsules/day) for 6 months
placebo
3 g/day (3 capsules/day) for 6 months

Locations

Country Name City State
Israel Beersheva Mental Health Center Beersheva
Israel Tirat Carmel Mental Health Center Tirat Carmel

Sponsors (2)

Lead Sponsor Collaborator
Beersheva Mental Health Center Tirat Carmel Mental Health Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Positive and Negative Symptoms Scale (PANSS) baseline and every week 4 up to 24 weeks up to 24 weeks
Secondary Clinical Global Impression - Improvement (CGI-I) baseline and every week 4 up to 24 weeks up to 24 weeks
Secondary Clinical Global Impression - Severity of Adverse Events (CGI-SAE) baseline and every week 4 up to 24 weeks up to 24 weeks
Secondary Calgary Depression Scale for Schizophrenia (CDSS) baseline and every week 4 up to 24 weeks up to 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT00161044 - An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms N/A
Completed NCT01450514 - POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia Phase 2
Completed NCT05809882 - Study of Experience of High-frequency Repetitive Transcranial N/A
Recruiting NCT05948696 - Experience of Horticultural Group Therapy Among People With Chronic Schizophrenia
Completed NCT06206798 - Resourcefulness Group Intervention on Recovery and Quality of Life N/A
Completed NCT01761383 - Role of Nintendo Wii in Improving Negative Symptoms and Quality of Life in Chronic Schizophrenia N/A
Completed NCT01891929 - Cognitive Remediation and Sheltered Employment in Schizophrenia N/A
Completed NCT03275909 - Integrated Psychological Therapy for Chronic Schizophrenia N/A
Recruiting NCT00525863 - Oxygen Therapy in Schizophrenia Phase 3
Completed NCT02624167 - A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia Phase 2
Completed NCT00789698 - Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia Phase 3
Recruiting NCT06349369 - Effect of tDCS on Inflammatory Biomarkers in Chronic Schizophrenia N/A
Completed NCT02421146 - The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study N/A
Active, not recruiting NCT00664274 - Relation of Catechol-O-methyltransferase (COMT) Genotype and Response to Cognitive Remediation Schizophrenia N/A
Terminated NCT00148616 - Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia Phase 3